Euroscreen S.A.

Product Pipeline

Euroscreen is developing lead compounds across a number of therapeutic areas, with our own programs targeting applications for unmet medical needs.

Euroscreen will use its drug candidate Portfolio to maximize value and profit from partnerships at the preclinical stage. Lead compounds currently in development are on-track to enter clinical development in 2010.

 
Product Indication Development Timeline 
  (Target) GPCR/Cmpd IP Lead Selection IND-track Clinical (Ph.I)
ESN-280 Type II Diabetes(GPR43 modul.) ___________________________________ 
ESN-364Partnered with Cephalon CNS(target undisclosed) _________________________ 
ESN-196 HIV/AIDS(CCR5 agonist) _____________________________  Lead compound available for partnering
                          ____09/2007    ____09/2008   ____09/2009
 
You are here  :Home arrow Discovery Programs